Long-Term Outcome Following Three-Dimensional Conformal/Intensity-Modulated External-Beam Radiotherapy for Clinical Stage T3 Prostate Cancer

European Urology

Volumn 53, Issue 6, 2008, Pages 1172-1179

  Zelefsky, Michael J ^a   Yamada, Yoshiya ^a   Kollmeier, Marisa A ^a   Shippy, Alison M ^a   Nedelka, Michelle A ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Hormone therapy; IMRT; Prostate cancer; Radiotherapy; Stage T3

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CONTROL; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; COMPUTER ASSISTED RADIOTHERAPY; CONTROLLED STUDY; DISEASE SEVERITY; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; HORMONAL THERAPY; HUMAN; HUMAN TISSUE; INTENSITY MODULATED RADIATION THERAPY; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; METASTASIS; PRIORITY JOURNAL; PROGNOSIS; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; RADIATION DOSE; RECTUM DISEASE; RISK REDUCTION; SEMINAL VESICLE; TREATMENT FAILURE; TREATMENT OUTCOME; URINARY DYSFUNCTION;

AGED; AGED, 80 AND OVER; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROSTATIC NEOPLASMS; RADIOTHERAPY, INTENSITY-MODULATED; TIME FACTORS; TREATMENT OUTCOME;

EID: 42749093784     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2007.12.030     Document Type: Article

References (26)

1. Pilepich M.V., Winter K., Lawton C.A., et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma-long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys 61 (2005) 1285-1290
2. Bolla M., Collette L., Blank L., et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 360 (2002) 103-106
3. Pilepich M.V., Winter K., John M.J., et al. Phase III Radiation Therapy Oncology Group (RTOG) Trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 50 (2001) 1243-1252
4. Hanks G.E., Pajak T.F., Porter A., et al. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate. The Radiation Therapy Oncology Group Protocol 92-02. J Clin Oncol 21 (2003) 3972-3978
5. Roach III M., Desilvio M., Lawton C., et al. Phase III trial comparing whole-pelvic verus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413. J Clin Oncol 21 (2003) 1904-1911
6. D'Amico A.V., Manola J., Loffredo M., et al. 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized control trial. JAMA 292 (2004) 821-827
7. Van den Ouden D., Hop W.C.J., and Schroder F.H. Progression in and survival of patients with locally advanced prostate cancer (T3) treated with radical prostatectomy as monotherapy. J Urol 160 (1998) 1392-1397
8. Gontero P., Marchioro G., Pisani R., et al. Is radical prostatectomy feasible in all cases of locally advanced non-bone metastatic prostate cancer? Results of a single institution study. Eur Urol 51 (2007) 922-930
9. Freedland S.J., Partin A.W., Humphreys E.B., et al. Radical prostatectomy for clinical stage T3a disease. Cancer 109 (2007) 1273-1278
10. Powell I.J., Tangen C.M., Miller G.J., et al. Neoadjuvant therapy before radical prostatectomy for clinical T3/T4 carcinoma of the prostate: 5-year follow-up, phase II Southwest Oncology Group Study 9109. J Urol 168 (2002) 2016-2019
11. Carver B.S., Bianco F.J., Scardino P.T., and Eastham J.A. Long-term outcome following radical prostatectomy in men with clinical stage T3 prostate cancer. J Urol 176 (2006) 564-568
12. Loeb S., Smith N.D., Roehl K.A., and Catalona W.J. Intermediate-term potency, continence, and survival outcomes of radical prostatectomy for clinically high-risk or locally advanced prostate cancer. Urology 69 (2007) 1170-1175
13. Ward J.F., Slezak J.M., Blute M.L., et al. Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate specific antigen testing: 15-year outcome. BJU Int 95 (2005) 751-756
14. Hanks G.E., Krall J.M., Hanlon A.L., et al. Patterns of care and RTOG studies in prostate cancer: long-term survival, hazard rate observations and possibilities of cure. Int J Radiat Oncol Biol Phys 28 (1994) 39-45
15. Zagars G.K., Johnson D.E., von Eschenbach A.C., and Hussey D.H. Adjuvant estrogen following radiation therapy for stage C adenocarcinoma of the prostate: long-term results of a prospective randomized study. Int J Radiat Oncol Biol Phys 14 (1988) 1085-1091
16. Zietman A.L., Westgeest J.C., and Shipley W.U. Radiation based approaches to the management of T3 prostate cancer. Semin Urol Oncol 15 (1997) 230-238
17. Zelefsky M.J., Leibel S.A., Gaudin P.B., et al. Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer. Int J Radiat Oncol Biol Phys 41 (1998) 491-500
18. Burman C.M., Chui C.S., Kutcher G.J., et al. Planning, delivery, and quality assurance of intensity-modulated radiotherapy using dynamic multileaf collimator: a strategy for large-scale implementation for the treatment of carcinoma of the prostate. Int J Radiat Oncol Biol Phys 39 (1997) 863-873
19. Thames E.M., Kuban D.A., Levy L.B., et al. Comparison of alternating biochemical failure definitions based on clinical outcome in 4839 prostate cancer patients treated by external radiation therapy between 1986 and 1995. Int J Radiat Oncol Biol Phys 57 (2003) 929-943
20. Kaplan E.L., and Meier P. Nonparametic estimation from incomplete observations. J Am Stat Assoc 53 (1959) 447-457
21. Mantel N. Evaluation of survival data and two rank order statistics arising in its consideration. Cancer Chemo Rep 50 (1966) 163-168
22. Cox D.R. Regression models and life tables. J Roy Statist Soc 34 Series B (1972) 187-220
23. Hsu C.-Y., Joniau S., Oyen R., et al. Outcome of surgery for clinical unilateral T3a prostate cancer: a single-institution experience. Eur Urol 51 (2007) 121-129
24. Poppel H.V., Vekemans K., Pozzo L.D., et al. Radical prostatectomy for locally advanced prostate cancer: results of a feasibility study (EORTC 30001). Eur J Cancer 42 (2006) 1062-1067
25. Zelefsky M.J., Chan H., Hunt M., et al. Long-term outcome of high dose intensity modulated radiation therapy for patients with clinically localized prostate cancer. J Urol 176 (2006) 1415-1419
26. Joniau S., Hsu C.-Y., Lerut E., et al. A pretreatment table for the prediction of final histopathology after radical prostatectomy in clinical unilateral T3a prostate cancer. Eur Urol 51 (2007) 388-396